Silver Spring-based United Therapeutics' quarterly sales got a boost from its newest treatment for pulmonary arterial hypertension, while higher research and development costs, and a bigger payroll, dragged down the bottom line.
United Therapeutics had second quarter revenue of $347.2 million, up 7.5 percent from $322.8 million in revenue in the same quarter a year earlier. Net income was $99.2 million, or $1.91 per share, compared to net income of $111.9 million, or $2.10 per share a year ago.